STOCK TITAN

Travere Therapeutics (TVTX) director sells 9,750 shares via 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Travere Therapeutics, Inc. director Roy D. Baynes carried out an exercise-and-sell transaction involving company stock. On May 1, 2026, he exercised stock options to acquire 9,750 shares of common stock at $6.82 per share, then sold 9,750 shares in an open-market transaction at $44.22 per share.

The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025, indicating it was scheduled in advance. Following these transactions, Baynes directly holds 37,500 shares of Travere common stock, and the exercised option is now fully vested and exercisable with no remaining derivative position from that specific grant.

Positive

  • None.

Negative

  • None.
Insider Baynes Roy D.
Role null
Sold 9,750 shs ($431K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 9,750 $0.00 --
Exercise Common Stock 9,750 $6.82 $66K
Sale Common Stock 9,750 $44.22 $431K
Holdings After Transaction: Stock option (right to buy) — 9,750 shares (Direct, null); Common Stock — 47,250 shares (Direct, null)
Footnotes (1)
  1. This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. The stock option is fully vested and exercisable.
Shares sold 9,750 shares Common stock sold in open market on May 1, 2026
Sale price $44.22 per share Price for 9,750 Travere common shares sold
Options exercised 9,750 shares Common shares acquired via option exercise on May 1, 2026
Option exercise price $6.82 per share Strike price for exercised Travere stock option
Shares held after sale 37,500 shares Total Travere common shares owned directly post-transaction
Option expiration date May 8, 2034 Expiration for the exercised 9,750-share stock option
Rule 10b5-1(c) regulatory
"written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
stock option financial
"The stock option is fully vested and exercisable."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
fully vested and exercisable financial
"The stock option is fully vested and exercisable."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Baynes Roy D.

(Last)(First)(Middle)
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DR., SUITE 300

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026M9,750A$6.8247,250D
Common Stock05/01/2026S(1)9,750D$44.2237,500D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$6.8205/01/2026M9,750 (2)05/08/2034Common Stock9,750$09,750D
Explanation of Responses:
1. This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
2. The stock option is fully vested and exercisable.
/s/ Elizabeth E. Reed, Attorney-in-Fact05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Travere Therapeutics (TVTX) director Roy D. Baynes report on this Form 4?

Director Roy D. Baynes reported exercising stock options for 9,750 Travere shares at $6.82 and selling 9,750 shares at $44.22. The filing shows an exercise-and-sell sequence rather than a pure open-market purchase or sale of existing holdings.

How many Travere Therapeutics (TVTX) shares did Roy D. Baynes sell and at what price?

Roy D. Baynes sold 9,750 Travere Therapeutics common shares in an open-market transaction at $44.22 per share. These shares came from stock options he exercised the same day, rather than long-held common stock, according to the Form 4 disclosure.

What stock options did Roy D. Baynes exercise in Travere Therapeutics (TVTX)?

He exercised stock options covering 9,750 Travere common shares at a $6.82 exercise price. The options were fully vested and exercisable, and the filing links this option exercise directly to the 9,750 common shares later sold in the open market.

Was Roy D. Baynes’ Travere Therapeutics (TVTX) share sale pre-planned under Rule 10b5-1?

Yes. The Form 4 states the sale was made under a written trading plan adopted November 17, 2025, that meets Rule 10b5-1(c) requirements. Such plans pre-schedule trades to help separate routine liquidity management from discretionary market timing decisions.

How many Travere Therapeutics (TVTX) shares does Roy D. Baynes hold after these transactions?

After the reported transactions, Roy D. Baynes directly holds 37,500 Travere common shares. This post-transaction balance, disclosed in the Form 4, helps investors see that he continues to maintain a meaningful equity position in the company.

What is the expiration date of the Travere Therapeutics (TVTX) stock option exercised by Roy D. Baynes?

The exercised stock option, covering 9,750 Travere common shares at a $6.82 exercise price, has an expiration date of May 8, 2034. The Form 4 notes that this option was fully vested and exercisable at the time of the reported transaction.